Floatz logo

10 assets in Diffuse Midline Glioma, H3 K27M-Mutant

Therapeutic assets addressing Diffuse Midline Glioma, H3 K27M-Mutant, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ribociclib
Diffuse Midline Glioma, H3 K27M-Mutant
Nationwide Children's HospitalP2B (60)
Everolimus
Diffuse Midline Glioma, H3 K27M-Mutant
Nationwide Children's HospitalP2CCC (53)
Olutasidenib
Diffuse Midline Glioma, H3 K27M-Mutant
Rigel PharmaceuticalsP2CCC (53)
Pegargiminase
Diffuse Midline Glioma, H3 K27M-Mutant
Sabine Mueller, MD, PhDP1/2CC (47)
Amxt1501
Diffuse Midline Glioma, H3 K27M-Mutant
Aminex Therapeutics, Inc.P1/2CC (45)
Eflornithine
Diffuse Midline Glioma, H3 K27M-Mutant
Aminex Therapeutics, Inc.P1/2CC (45)
b7-h3-car t cells
Diffuse Midline Glioma, H3 K27M-Mutant
St. Jude Children's Research HospitalP1CC (41)
Onc 206
Diffuse Midline Glioma, H3 K27M-Mutant
Jazz PharmaceuticalsP1CC (41)
S-Gboxin
Diffuse Midline Glioma, H3 K27M-Mutant
Petrov, AndreyP1CC (41)
Triapine
Diffuse Midline Glioma, H3 K27M-Mutant
National Cancer Institute (NCI)P1NR ()